Fluorination and Fluoroalkylation Strategies for Synthetic and Medicinal Chemistry

The Altman group's R35 program aims to develop innovative catalyst systems, reagents, and synthetic strategies for accessing medicinally relevant fluorinated substructures. This involves using methodologies like electrochemistry, C–H functionalization, deoxyfluoroalkylation, and transition metal catalyzed reactions to convert simple functional groups into valuable fluorinated analogs. A secondary goal is to explore physicochemical perturbations by fluorinated substructures to influence drug stability, distribution, metabolism, and ligand-protein interactions, applying these principles to design next-generation fluorinated therapeutic candidates with improved drug-like properties, specifically focusing on natural product analogs.